Prostate Cancer Clinical Trial
MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer
This phase II trial tests whether magnetic resonance imaging (MRI)-guided hypofractionated radiation therapy works to reduce treatment time and side effects in patients with high risk prostate cancer. MRI-guided hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time directly to diseased tissue, reducing damage to healthy tissue. Using MRI-guided radiation therapy on areas of the prostate and pelvic lymph nodes may shorten overall treatment time compared to the longer standard of care therapy and may reduce the number and/or duration of side effects.
I. Evaluate late grade 2+ genitourinary (GU) toxicity.
I. Evaluating acute GU and gastrointestinal (GI) toxicity, late GI toxicity, overall survival, prostate cancer specific survival, biochemical failure, and quality of life.
Patients undergo MRI-guided intensity-modulated radiation therapy (IMRT) on study and receive standard of care (SOC) antiandrogen therapy (ADT) throughout the trial. Patients may also undergo prostate specific membrane antigen (PSMA) positron emission tomography (PET), computed tomography (CT), MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.
Age: above 18 years
Participants must be histologically proven, adenocarcinoma prostate
Localized to the prostate without positive pelvic lymph node involvement
No distant metastatic disease assessed by pretreatment PSMA PET or bone scan and CT scan
High risk prostate cancer as defined by National Comprehensive Cancer Network (NCCN): Gleason score of 8-10, clinical stage T3a or higher, or prostate specific antigen (PSA) > 20 ng/mL
Ability to receive long term hormone therapy
Karnofsky performance score (KPS) > 70
No prior history of therapeutic irradiation to pelvis
Patient willing and reliable for follow-up and quality of life (QOL)
Evidence of distant or pelvic metastasis at any time since presentation
Life expectancy < 2 years
Previous radiation therapy (RT) to prostate or prostatectomy
A previous trans-urethral resection of the prostate (TURP)
Severe urinary symptoms or with severe International Prostate Symptom Score (IPSS) score despite being on hormonal therapy for 6 months which in the opinion of the physician precludes RT
Patients with known obstructive symptoms with stricture
Any contraindication to radiotherapy such as inflammatory bowel disease
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19107, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.